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ABSTRACT
Chronic myeloid leukaemia (CML) is a relatively rare disease in children, accounting for 2–3% of all paedi-
atric leukaemia cases. Generally, children with CML can avoid hematopoietic stem cell transplantation and
achieve molecular responses with tyrosine kinase inhibitors (TKI). However, CML stem cells are thought to
survive in many patients, even after TKI treatment. Many aspects of the toxic effects of prolonged exposure
to TKIs during childhood remain unclear, particularly those regarding growth impairment. This lack of
clarity underscores the importance of the present clinical trial, which aims to clarify the feasibility of
treatment-free remission (TFR) in children following TKI treatment. We aim to examine the long-term out-
comes and complications of TKIs before and after cessation to better understand the unknown complications
that could arise in adulthood. This trial targets patients who were diagnosed with CML at an age younger
than 20 years, were in the chronic or accelerated phase at initial diagnosis and remained in complete molec-
ular remission for at least 2 years after TKI administration. We will examine the utility of TKI cessation and
assess the treatment results of patients who resumed TKI therapy after losing a major molecular response.
We will also investigate factors related to the feasibility of a TFR after TKI cessation.
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Chronic myeloid leukaemia (CML) is a relatively rare
disease in children, accounting for 2–3% of all paediat-
ric leukaemia cases. Most CML patients are diagnosed
during adolescence13), and the median age at diagnosis is
approximately 11–12 years. The Philadelphia chromo-
some (Ph) is reported to be present in 95% of all CML
cases18). This chromosomal aberration derives from
t(9;22)(q34;q11), a balanced translocation of the long
arms of chromosomes 8 and 22. Consequently, the ABL
gene at 9q34 and the BCR gene at 22q11 form the chi-
meric BCR-ABL gene, which expresses the constitutively
active tyrosine kinase, BCR-ABL. In cells, BCR-ABL sub-
sequently activates various downstream signalling path-
ways associated with the Ras/MAP, PI3/AKT, and Jak/
STAT pathways and thus promotes the production of
growth factor-independent cell clones. Accordingly,
BCR-ABL contributes to the onset and persistence of leu-
kaemia. At the initial onset of CML, granulocytosis (≥3%
basophils) and thrombocytosis appear in the peripheral
blood, whereas splenomegaly occurs as the disease pro-
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gresses. Patients younger than 20 years exhibit the fol-
lowing disease phases when they are first diagnosed:
chronic phase (89%), accelerated phase (4%) and blastic
phase (7%). In other words, most cases are diagnosed
during the chronic phase4).
The International Randomized Study of Interferon
versus STI571 (IRIS) trial of adults with chronic-phase
CML demonstrated the dramatic effectiveness and safety
of imatinib, a tyrosine kinase inhibitor (TKI), and thus
reduced the merits of allogeneic hematopoietic stem cell
transplantation in patients with chronic-phase disease3).
Although clinical trials of imatinib for paediatric CML
are limited, the effects of this agent in children are
expected to be similar to those observed in adults.
Accordingly, imatinib is now widely used to treat
chronic-phase paediatric CML.
In phase I trials of imatinib conducted by the Child-
ren’s Oncology Group, the complete cytogenetic response
(CCyR) rate was 83% in a 20-case cohort of patients with
chronic-phase CML in whom interferon was ineffective2).
In European phase II trials of advanced or relapsed
CML, the CCyR rate was 60% among 20 cases of paediat-
ric chronic-phase CML and 29% among 7 cases of
advanced-phase CML. In contrast, no patients with
advanced CML achieved a molecular response9). In phase
IV trials for imatinib in France, the 12-month CCyR and
major molecular response (MMR) rates were 62% and
34%, respectively, among 44 children with chronic-phase
CML8). A phase IV clinical trial of imatinib for 47 chil-
dren of chronic-phase CML in Berlin-Frankfurt-Munster
(BFM), Germany, has preliminarily reported a 12-month
CCyR rate of 93% and 18-month MMR rate of 85%19). In
2007, a Japanese national study of 166 cases of CML in
children aged <18 years reported favourable results. In
another study of 76 chronic cases treated initially with
imatinib, the 12-month CCyR achievement rate was
79%, the 5-year survival rate was 92%, and the 5-year
progression-free survival rate was 91% (the cutoff at
time of transfer was 30 cases).
Many paediatric chronic-phase CML patients can
avoid hematopoietic stem cell transplantation and ach-
ieve a molecular response with imatinib and second-
generation TKIs. However, CML stem cells may survive
in many patients, even after treatment with TKI10).
Furthermore, many aspects regarding the toxic effects of
prolonged exposure to TKIs during childhood remain
unclear. In particular, the potential contribution of TKI
use to growth impairment is concerning17,19). In a 2007
national study of paediatric patients with chronic-phase
CML, 73% of 48 patients exhibited a decrease in their
growth standard deviation scores (SDSs) during a mean
imatinib treatment duration of 34 months, compared
with the SDSs at the beginning of treatment (+0.01 at
diagnosis vs. –0.85 after treatment). Marked growth
impairment was also observed in younger children (i.e.,
those who initiated imatinib therapy before adoles-
cence). Long-term follow-up data are needed to evaluate
the extent of eventual growth impairment associated
with TKI use. Additionally, it is important to conduct
clinical trials of TKI cessation and to examine the long-
term outcomes and complications of TKI use with the
aim of avoiding unknown complications in adulthood.
SUBJECTS AND METHODS
Study design
This study was a multi-centre, open-label, single arm
trial and has been registered in the University Hospital
Medical Information Network (UMIN) clinical trial reg-
istry (UMIN000017644).
Currently, there are limited studies that focus on the
discontinuation of imatinib in children with CML. How-
ever, it is presumed that paediatric patients who sustain
long-term complete molecular response (CMR) may be
able to discontinue imatinib as many adult patients are
able to do. This assumption may be made since molecu-
lar genetic characteristics of CML cells are similar in
adults and children20). Furthermore, the treatment
results with imatinib for children with CML are equiva-
lent to those in adults21). For our research, we will con-
duct a study of TKI cessation in patients with CML
younger than age 20 in the chronic or accelerated phase
at initial diagnosis, and who remained in complete
molecular remission for at least 2 years after TKI admin-
istration. Our research is based on the evidence obtained
from studies that evaluated the discontinuation of imati-
nib in adults with CML. This study aims to assess the
utility of TKI cessation by evaluating the duration of
treatment-free remission (TFR) and the treatment effect
in those patients who resumed TKI.
Eligibility criteria
Inclusion criteria
1) Patients with BCR-ABL chimeric gene-positive CML.
2) Patients who present with the chronic or accelerated
phase when first diagnosed.
3) Patients younger than 20 years of age at diagnosis.
4) A total TKI treatment period of ≥3 years; in cases of
stem cell rejection, the total treatment period after
rejection should be ≥3 years.
5) A complete molecular response (CMR) has been
maintained for ≥2 years after TKI treatment.
6) The peripheral blood concentration of major BCR-
ABL/ABL messenger RNA (mRNA) ratio is <0.01% on
the International Scale within 4 weeks prior to regis-
tration.
7) The Eastern Cooperative Oncology Group perform-
ance status score is 0–2 at the time of registration.
8) The patient has sufficient organ function according to
laboratory data obtained within 7 days prior to regis-
tration, thus simultaneously fulfilling conditions (i)
and (ii) below.
(i) Total bilirubin: The total bilirubin concentration is
no more than three times the upper limit of normal for
the patient’s age (Table 1).
(ii) Creatinine: The creatinine concentration is no
more than three times the upper limit of normal for
the patient’s age (Table 1).
9) Informed written consent from the patient or their
legal representative is obtained before participation in
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this trial.
Exclusion criteria
1) The patient has a history of progression to the blastic
phase of CML.
2) The patient has a central nervous system haemor-
rhage of grade three or higher, based on the Common
Terminology Criteria for Adverse Events, Version 4.0.
3) The patient has an uncontrolled infectious disease
(including active tuberculosis and human immunode-
ficiency virus infection).
4) The patient is pregnant, nursing, or has a high proba-
bility of becoming pregnant.
5) The patient has a history of congenital or acquired
immunodeficiency.
6) The Fridericia-revised QTc value at registration is
≥0.45 seconds according to the following formula:
QTc = QT/RR*1/3
7) The patient is deemed unsuitable for the trial by the
attending physician(s).
Sample size
The threshold for the TFR rate has been set according
to the achievements of adult chronic-phase CML
patients. Japanese trials have defined a molecular
relapse as >100 copies/0.5 μg RNA of Amp-CML, and
the 12-month recurrence-free survival rate after imatinib
cessation was 58.1% (n = 41)7). In the STIM trial, TKI
treatment was restarted when an MMR was lost, and the
12-month CMR maintenance rate after imatinib cessa-
tion was 41% (95% confidence interval [CI], 29–52%; n
= 69)5,6). The CML8 TWISTER study considered a CMR
loss to be the standard criterion required for a TKI
restart, and the reported 24-month TFR rate was 47% (n
= 40)15). With reference to these data, we set the TFR
rate threshold at 40%. Furthermore, we set the expected
TFR rate at 64% per the achievements reported in A-
STIM, which assumed that a resumption of standard
treatment indicated an MMR loss (major BCR-ABL/ABL
mRNA ratio in the peripheral blood >0.1% [international
scale]). The calculated sample size of 24, with a one-
sided significance level of 0.05 and statistical power of
0.80, was based on the non-parametric method for sur-
vival time1). We set the sample size at 25 in consideration
of potentially ineligible patients.
Treatment plan
TKI treatment is ceased immediately after the registra-
tion of each patient. We then monitor the patient and
maintain TKI cessation for as long as the patient remains
in a state of MMR. A molecular relapse is determined to
have occurred if even one MMR loss is confirmed; this
depends on the amount of major BCR-ABL mRNA
detected in the peripheral blood. For patients with a
molecular relapse, we perform a bone marrow examina-
tion (G banding technique) and restart the same TKI that
had been stopped within 7 days after the confirmation of
an MMR loss. We then evaluate the treatment effective-
ness by monitoring the patient after restarting TKI ther-
apy. The study design flowchart is shown in Figure 1.
Monitoring after TKI cessation
1) The following tests will be performed for up to 12
months following TKI cessation:
(i) The major BCR-ABL/ABL mRNA ratio in the
peripheral blood will be assessed monthly. A ratio
exceeding 0.1% even once will indicate a molecular
relapse (MMR loss). In addition, if the concentration
exceeds 0.01% after 12 months, this parameter will be
re-tested during the following month.
(ii) Immune system markers in the peripheral blood
will be assessed at months 1, 3, 6, and 12.
(iii) Natural killer (NK) cell activity will be assessed at
months 6 and 12.
(iv) A quality of life (QOL) survey will be administered
at months 2, 6, and 12.
Table 1. Normal Laboratory Ranges by Age22)
Age (years) Total bilirubin: enzymatic method Creatinine: enzymatic methodUpper limit (male and female) Upper limit (male) Upper limit (female)
1 0.67 0.33 0.33
2 0.80 0.38 0.35
3 0.85 0.40 0.38
4 0.85 0.43 0.41
5 0.85 0.47 0.45
6 0.85 0.50 0.48
7 0.85 0.53 0.51
8 0.85 0.57 0.55
9 0.90 0.60 0.60
10 0.95 0.65 0.65
11 1.00 0.70 0.69
12 1.10 0.78 0.71
13 1.20 0.85 0.73
14 1.25 0.90 0.74
15 1.30 0.95 0.75
16 1.35 0.98 0.75
17 1.40 1.00 0.75
18 1.40 1.00 0.75
19 1.40 1.00 0.75
20 1.40 1.00 0.75
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2) The following tests will be performed from 13 to 24
months after TKI cessation:
(i) The major BCR-ABL/ABL mRNA ratio in the peri-
pheral blood will be assessed every 2 months starting
from month 14. A ratio exceeding 0.1% even once will
indicate a molecular relapse (MMR loss). In addition,
if this concentration exceeds 0.01% after 12 months,
we will re-test this parameter during the following
month.
(ii) Immune system markers in the peripheral blood
will be assessed at 24 months.
(iii) A QOL survey will be administered at 24 months.
3) The following tests will be performed from 25 to 36
months after TKI cessation:
(i) The major BCR-ABL/ABL mRNA ratio in the
peripheral blood will be assessed every 3 months from
month 27.
A ratio exceeding 0.1% even once will indicate a molecu-
lar relapse (MMR loss). In addition, if this concentration
exceeds 0.01% after 12 months, we will re-test this
parameter during the following month to determine
whether this increase reflects a temporary exacerbation.
Monitoring after restarting TKI therapy
The following tests will be performed up to the end of
the study period:
(i) The major BCR-ABL/ABL mRNA ratio in the
peripheral blood will be assessed every month after
resuming TKI use. The frequency of testing can be
reduced to a minimum of once every 3 months if two
consecutive results yield ratios <0.01%.
(ii) Immune system markers in the peripheral blood
will be assessed 1, 3, and 6 months after resuming
TKI.
(iii) Bone marrow examinations (G banding techni-
que) will be performed and bone marrow markers will
be assessed (only in patients with CCyR losses prior to
resuming the TKI) at months 1, 3, 6, and 12 after
restarting TKI. This is not required if the criteria for
CCyR are met on two consecutive occasions or if the
Patient registration
Consent given and eligibility confirmed
TKI cessation sustained
The patients remain in 
a state of MMR
One MMR loss is 
confirmed
TKI cessation
TKI resumption
Evaluation of the treatment 
effectiveness
Figure 1. Study Design Flowchart
criteria for MMR are fulfilled even once.
(iv) A QOL survey will be administered 2 and 12
months after restarting TKI and 24 months after TKI
cessation.
Outcomes
Primary outcome
The primary outcome of this study is the 12-month
TFR rate after TKI cessation. The duration of TFR is
defined from TKI withdrawal to TKI restart for any rea-
son or to the last observation date if TKI is not resumed.
Secondary outcomes
1. The cumulative incidence of 12-month MMR loss after
TKI cessation.
The MMR loss is defined as at least one peripheral
blood major BCR-ABL/ABL mRNA ratio exceeding
0.1%. The duration of MMR maintenance is defined as
the interval from the date of TKI cessation to the date of
MMR loss. Patients who do not experience a MMR loss
or death will be censored on the last observation day.
2. The cumulative 12-month incidence of CMR loss after
TKI cessation.
A CMR loss is defined as two or more consecutive
peripheral blood major BCR-ABL/ABL mRNA ratios of
at least 0.01%; if the value exceeds 0.1%, however, the
requirement for two consecutive conditions is waived.
The duration of CMR maintenance is defined as the
interval from the date of TKI discontinuation to the date
of CMR loss. Patients who do not experience a CMR loss
or death will be censored on the last observation day.
3. Factors related to TFR.
4. The cumulative incidence of MMR after TKI resump-
tion.
5. The cumulative incidence of CMR after TKI resump-
tion.
6. The growth rates at the time of TKI cessation, during
MMR maintenance, and after TKI resumption.
7. Changes in the QOL at the time of TKI cessation,
during MMR maintenance, and after TKI resumption.
8. The occurrence of adverse events at the time of TKI
cessation, during MMR maintenance, and after TKI
resumption.
9. Long-term toxicity.
Data collection
The registered data of the enrolled patients will be col-
lected from participating facilities and submitted via an
electronic data capture system.
Statistical analysis
Definition of the analysis datasets
1) The full analysis set comprises all registered and eligi-
ble patients who stopped TKI use, excluding cases
with errors in the data, multiple entries, and ineligible
data.
2) The resumed TKI analysis set consists of all patients
who resumed TKI use.
The whole-study efficacy and safety analysis will use
the full analysis set. The post-TKI resumption efficacy
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and safety analysis will use the resumed TKI analysis set.
Primary endpoint analysis
The Kaplan–Meier method will be used to estimate the
cumulative TFR curve after TKI cessation. The confi-
dence interval for the median duration of TFR will be
calculated using the Brookmeyer and Crowley method1).
The 90% confidence interval for the 12-month TFR rate
will be calculated using the Greenwood formula.
Secondary endpoint analysis
The cumulative MMR loss incidence will be calculated
as the cumulative MMR loss incidence function for all
patients that stopped TKI use, after considering compet-
ing risks such as TKI resumption prior to a MMR loss.
The incidence of CMR loss and the cumulative inciden-
ces of MMR or CMR after TKI resumption will be deter-
mined similarly.
Factors such as the performance status score, Lansky
score, duration of TKI use prior to the start of the trial,
duration of CMR maintenance prior to the cessation of
TKI, duration required to achieve CMR prior to the ces-
sation of TKI, treatment history prior to the start of the
trial, risk score (e.g., Sokal score, Hasford score, EUTOS
score) at diagnosis, blood concentration of imatinib at
TKI cessation, age at diagnosis and TKI cessation, sex,
number of immunocytes including lymphocytes and level
of NK activity during the trial, as well as the correlations
of these factors with TFR, will be assessed using a Cox
proportional hazards model.
The growth-SDS for the growth rate, the QOL, and the
occurrences of adverse events will be determined at TKI
cessation, during MMR maintenance, and after TKI
resumption.
Ethics committee procedure and consent for the
study
This trial was approved by the Clinical Research Com-
mittee of the Japanese Society of Pediatric Hematology/
Oncology and the Ethics Committee of the Keio Univer-
sity School of Medicine.
Written informed consent was obtained from every
participant and/or their legal guardian in the study.
Patient recruitment
Patients were recruited at participating institutions
that were approved by the Ethics Review Committee for
this study. After confirming the eligibility for registration
based on the inclusion criteria, case registration was con-
ducted in the electronic data capturing system.
Adverse events
Common Terminology Criteria for Adverse Events
Version 4.0 is used for evaluation of adverse events.
Adverse events falling under any of the following are
subject to emergency reporting.
(1) Unexpected non-haematological toxicity of grade 4.
(2) All deaths occurring within 30 days from start of
protocol treatment to the final administration of inves-
tigational drugs.
Safety considerations
If any of the following occurs during the protocol
period, the principal investigator (PI) consults the Data
and Safety Monitoring Board (DSMB) on discontinua-
tion of the study.
(1) A case of blast crisis occurs.
(2) The number of recurrence cases reaches 14.
The DSMB consists of three experts in Haematology.
The DSMB reviews adverse events and recommends the
review results for future response including the continu-
ation of registration and the necessity of protocol
amendment.
Organization structure
Hiroyuki Shimada is the principal investigator and
Haruko Shima is the research secretariat in this study. A
total of 32 institutions that belong to Japanese Pediatric
Leukemia/Lymphoma Study Group (JPLSG) participate
in the study.
DISCUSSION
Currently, no domestic or international reports have
addressed whether it is possible to cease TKI treatment
in paediatric CML patients, despite the vital importance
of this topic. The existing data regarding the Sokal
score5,6,15), period of interferon administration15), treat-
ment status prior to interferon administration16), and
period of imatinib treatment5,6) vary significantly and
were extracted from trials of imatinib cessation in adults.
In addition, significantly lower levels of CD4-positive
regulatory T-cells (Tregs) have been observed in CML
patients who achieved a CCyR relative to those who did
not achieve CCyR14). Moreover, patients who responded
favourably to dasatinib had higher concentrations of NK
cells and cytolytic T cells, compared to those with unfav-
ourable responses11), and patients who maintained a
CMR after imatinib cessation were found to exhibit
higher NK cell ratios and activity levels12). Taken
together, these earlier findings suggest that tumour
immunity is an essential component of a permanent
CML cure. However, further research is needed because
it is difficult to precisely extract a group in which TKI
treatment can be ceased. Accordingly, the present study
is based on the concept that identifying the characteris-
tics of paediatric CML patients who can successfully
cease the use of TKIs such as imatinib will greatly con-
tribute to future treatment policies for this population.
Study status
This trial was approved by the clinical research com-
mittee of the Japanese Society of Pediatric Hematology/
Oncology on April 27, 2015. We began registering
patients on June 1, 2015 and concluded registration on
December 31, 2016. We plan to conclude the follow-up
period on December 31, 2018.
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